Novoprotein Scientific Inc. (SHA:688137)
China · Delayed Price · Currency is CNY 43.26
-0.25 (-0.57%)
At close: Feb 12, 2026
Novoprotein Scientific Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 147.18 | 127.4 | 153.05 | 264.33 | 341.79 | 179.73 |
Other Revenue | 0.15 | 0.15 | 0.14 | 0.22 | 0.11 | 0.11 |
| 147.33 | 127.56 | 153.19 | 264.55 | 341.9 | 179.84 | |
Revenue Growth (YoY) | 9.49% | -16.73% | -42.09% | -22.62% | 90.11% | 399.79% |
Cost of Revenue | 80.15 | 73.47 | 70.69 | 54.3 | 54.55 | 25.01 |
Gross Profit | 67.18 | 54.08 | 82.5 | 210.25 | 287.35 | 154.83 |
Selling, General & Admin | 101.51 | 101.09 | 87.84 | 82.94 | 69.29 | 39.93 |
Research & Development | 56.41 | 49.92 | 44.79 | 41.1 | 34.1 | 14.97 |
Other Operating Expenses | 16.62 | 1.29 | 0.67 | 3.01 | 3.9 | 2.86 |
Operating Expenses | 171.83 | 154.39 | 131.72 | 128.27 | 111.17 | 58.79 |
Operating Income | -104.65 | -100.31 | -49.22 | 81.98 | 176.17 | 96.04 |
Interest Expense | -2.8 | -3.59 | -3.59 | -4.05 | -1.8 | -1 |
Interest & Investment Income | 34.42 | 41.48 | 49.42 | 9.07 | 2.39 | 0.17 |
Currency Exchange Gain (Loss) | 0.71 | 0.71 | 0.65 | 2.84 | -0.81 | -2.18 |
Other Non Operating Income (Expenses) | -0.02 | -0.43 | -0.49 | -0.16 | -0.18 | -0.04 |
EBT Excluding Unusual Items | -72.34 | -62.14 | -3.23 | 89.69 | 175.77 | 92.99 |
Gain (Loss) on Sale of Investments | - | -1.8 | -1.75 | 3.55 | -0.14 | 0.14 |
Gain (Loss) on Sale of Assets | 0.78 | 0.05 | -0.09 | -0.04 | 0.03 | - |
Asset Writedown | -9.49 | -6.61 | - | - | -0.15 | -0.04 |
Other Unusual Items | 15.93 | 16.29 | 11.29 | 12.98 | 0.72 | 1.06 |
Pretax Income | -65.12 | -54.22 | 6.22 | 106.18 | 176.23 | 94.15 |
Income Tax Expense | -0.11 | 0.2 | -6.62 | 15.46 | 27.22 | 11.1 |
Net Income | -65.02 | -54.42 | 12.84 | 90.72 | 149.01 | 83.05 |
Net Income to Common | -65.02 | -54.42 | 12.84 | 90.72 | 149.01 | 83.05 |
Net Income Growth | - | - | -85.84% | -39.12% | 79.42% | - |
Shares Outstanding (Basic) | 70 | 70 | 71 | 57 | 40 | 16 |
Shares Outstanding (Diluted) | 70 | 70 | 71 | 57 | 40 | 16 |
Shares Change (YoY) | -3.27% | -2.23% | 25.05% | 42.83% | 151.52% | - |
EPS (Basic) | -0.93 | -0.78 | 0.18 | 1.59 | 3.73 | 5.23 |
EPS (Diluted) | -0.93 | -0.78 | 0.18 | 1.59 | 3.73 | 5.23 |
EPS Growth | - | - | -88.68% | -57.37% | -28.67% | - |
Free Cash Flow | -65.78 | -31.57 | 24.22 | -33.39 | 1.02 | 85.76 |
Free Cash Flow Per Share | -0.94 | -0.45 | 0.34 | -0.58 | 0.03 | 5.40 |
Dividend Per Share | - | - | 0.500 | 0.500 | - | - |
Gross Margin | 45.60% | 42.40% | 53.85% | 79.47% | 84.05% | 86.09% |
Operating Margin | -71.03% | -78.64% | -32.13% | 30.99% | 51.53% | 53.41% |
Profit Margin | -44.13% | -42.66% | 8.38% | 34.29% | 43.58% | 46.18% |
Free Cash Flow Margin | -44.65% | -24.75% | 15.81% | -12.62% | 0.30% | 47.69% |
EBITDA | -91.53 | -88.48 | -39.11 | 90.5 | 180.01 | 97.71 |
EBITDA Margin | -62.13% | -69.37% | -25.53% | 34.21% | 52.65% | 54.33% |
D&A For EBITDA | 13.12 | 11.83 | 10.11 | 8.52 | 3.83 | 1.67 |
EBIT | -104.65 | -100.31 | -49.22 | 81.98 | 176.17 | 96.04 |
EBIT Margin | -71.03% | -78.64% | -32.13% | 30.99% | 51.53% | 53.41% |
Effective Tax Rate | - | - | - | 14.56% | 15.45% | 11.79% |
Revenue as Reported | 147.33 | 127.56 | 153.19 | 264.55 | 341.9 | 179.84 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.